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tDITORIAL COMMENT
eappraisal of Implant
esting of Implantable
ardioverter Defibrillators*
harles D. Swerdlow, MD, FACC
os Angeles, California
or more than 20 years, detection and defibrillation of
entricular fibrillation (VF) have been tested at the implan-
ation of implantable cardioverter defibrillators (ICDs). In
his issue of the Journal, Strickberger and Klein (1) question
his practice. They propose that abandoning ICD testing
hould permit reduced training requirements for implanters
nd hence greater access to life-saving ICDs. Although
mplant testing attracts modest interest, training require-
ents attract great interest because they may substantively
ffect who implants ICDs and the economics of the medical
evice industry.
See page 88
HE RELATIONSHIP BETWEEN IMPLANT TESTING
ND TRAINING REQUIREMENTS FOR IMPLANTERS
he principal argument of Strickberger and Klein (1) for
bandoning defibrillation testing is that it limits access to
CDs. They begin by suggesting that the requirement for
mplant testing creates a barrier to ICD therapy “in regions
ith few or no electrophysiologists” and hence limited
apacity to perform such testing. Then, they extrapolate this
rgument to the national level. Finally, they propose a study
o “demonstrate that physicians without defibrillator im-
lantation experience can safely and appropriately implant
efibrillators [without testing].” These arguments rely on
everal questionable assumptions.
First, no study has established that a shortage of trained
mplanters creates a barrier to ICD therapy, even in remote
egions. High cost, lack of expert consensus on indications,
ack of perceived benefit by patients or physicians for
rimary prevention, disparities in insurance coverage, or
ther factors may be more important.
Second, the authors assume that more implant capacity
ill result in better outcomes on a national level by servicing
nmet need, but they provide no estimate of either need or
resent capacity. A work-time study sponsored by the
orth American Society of Pacing and Electrophysiology-
eart Rhythm Society determined that electrophysiologists
ave substantial excess implant capacity. They perform an
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.rFrom Cedars-Sinai Medical Center, Los Angeles, California.verage of three implants per month, spending only 12% of
heir time in implant-related activities (G. Naccarelli, per-
onal communication, January 2003), but a recent study (2)
stimated that ICDs were underused in urban areas despite
concentration of electrophysiologists who have unused
mplant capacity. If we make the conservative assumption
hat an electrophysiologist can implant two ICDs per week
ith testing, present implant capacity probably is in the
ange of two to three times the present volume. Once this
apacity is saturated, it is not axiomatic that “more is better.”
fter a threshold fraction of patients undergo coronary
nterventions, more interventions do not consistently im-
rove outcomes (3).
Third, although the authors focus on implant testing,
heir implicit thesis is that a putative shortage of electro-
hysiologists is the principal barrier to ICD therapy. Having
n insufficient supply of electrophysiologists perform all
CD care except implantation will not remove this barrier.
hus, the authors’ fundamental assumption is that physi-
ians who are not trained to perform defibrillation testing
an nevertheless provide comprehensive, quality care to
atients at risk for sudden death, but proficiency at implant
esting is only one of a number of differences between
raining requirements for ICD and pacemaker implantation
4). Both VF induced by inappropriate therapy for su-
raventricular tachycardia and untreated ventricular tachy-
ardia due to programming errors have caused sudden
eaths in ICD recipients (5). Multiple unnecessary shocks
elivered because of suboptimal programming may have a
ajor adverse effect on quality of life. To be meaningful, the
uthors’ study must test their fundamental assumption, that
hysicians without electrophysiologic training can provide
omprehensive care for ICD patients, including selection,
reoperative evaluation, implantation, programming, trou-
leshooting, follow-up, and management of drug-device
nteractions and recurrent ventricular tachyarrhythmias.
heir proposed trial does not address this comprehensive
ssue.
Fourth, the authors assume that the outcome of their
tudy will not be influenced strongly by the type of implant
esting used. However, different testing methods result in
ifferent recommendations about programming or system
evision, and experts disagree about which method is best.
efore considering a multicenter study of testing versus no
esting, it would be prudent either to identify optimal
esting or demonstrate that a clinically relevant range of
esting strategies results in similar outcomes.
The authors demonstrate that a randomized controlled
rial will be large, expensive, and time consuming. We need
etter data in at least four key planning areas before
onsidering one: 1) What is the optimal method for implant
esting? 2) Does implant testing limit access to indicated
CDs? If so, to what degree? 3) How safe is a trial of “no
esting” in a large prospectively selected subset of ICD
ecipients? Detection of VF may be unreliable if the R-wave
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July 7, 2004:92–4 Editorial Comments small. The high rate at which left-sided pectoral ICDs
ith right ventricular, apical defibrillation electrodes pass
he 10-J safety margin is in part due to implant testing.
uccess rates 95% are achieved only after implanters
hange shock waveform, lead position, or generator position
n 10% of patients (6). Defibrillation thresholds (DFTs)
re higher with right pectoral implants. Even with left
ectoral implants, experts disagree about whether lead
ositions other than the apex have consistently low DFTs.
ome of these situations cannot be anticipated preopera-
ively. 4) How will the study test the fundamental assump-
ion that physicians without electrophysiologic training can
rovide comprehensive care for ICD patients?
LTERNATIVE PERSPECTIVE
n alternative perspective is that implant testing should be
e-evaluated to determine the optimal balance between
mplant safety and long-term benefits of ICD therapy. The
ccuracy of defibrillation testing increases with the number
f VF episodes. Serious complications are rare with limited,
afety-margin testing (7), but a comprehensive assessment
f defibrillation efficacy is not performed in humans, be-
ause the risks of many VF episodes, including death, are
onsidered unacceptable.
However, limited testing provides limited assurance of
eliable defibrillation. The commonly used, 10-J safety
argin identifies only 50% of patients who have unreli-
ble defibrillation (8). Increases in DFTs that compromise
efibrillation efficacy occur in up to 15% of patients who are
rogrammed to a 10-J safety margin (9). Implantable
ardioverter defibrillators reduce the risk of sudden death
nly by 50% (10). In one study of ICD recipients, more
han half of sudden deaths were caused by shock failure or
ost-shock electromechanical dissociation (5). Some of the
ormer may be prevented by a more specific implant
riterion and some of the latter by programming lower,
atient-specific shock strengths that cause less post-shock
echanical dysfunction. Even if it were practical to implant
CDs that deliver uniformly effective shocks, unnecessarily
trong shocks would cause serious mechanical dysfunction
n many patients (7).
Strict, conventional defibrillation implant criteria subject
ll patients to multiple VF episodes and a significant
raction to unnecessary system revisions and retesting.
here is an inverse relationship between the fraction of
atients who pass any defibrillation implant criterion and
he subsequent success rate for conversion of spontaneous
evice-detected VF (8). Given the high, a priori probability
f successful defibrillation at implants performed by trained
mplanters, the rules of conditional probability dictate that
any patients with reliable defibrillation will not pass a
ighly specific implant criterion.
Thus, the implanter’s dilemma is that programming
ased on more specific testing may increase long-term
enefits of ICD therapy—but only at the price of greatermplant risk and complexity. Experts disagree on optimal
mplant criteria because they disagree about the trade-off
etween accuracy and risk. In this context, “no testing” is
ne end of a continuum that progresses with increasing
igor through limited safety-margin testing and DFT test-
ng to research DFT testing used only in animals.
New testing methods improve the predictive accuracy of
mplant testing with fewer or no episodes of VF. Bayesian
efibrillation testing is the most efficient method (11).
esting based on the upper limit of vulnerability permits the
ssessment of defibrillation efficacy without inducing VF in
0% to 90% of implants (12–14). An interleaved Bayesian
ombination of defibrillation and vulnerability testing is one
ethod to maximize the information derived from implant
esting. Clinical studies will be required to determine
hether new implant testing methods can improve out-
omes.
INANCIAL CONSIDERATIONS
“no-testing” standard will have financial implications for
mplanters, insurers, and industry. Some ICD manufactur-
rs favor reduced training requirements as a major oppor-
unity for increasing sales. They focus on “no testing” as a
rst step. Implantable cardioverter defibrillator manufactur-
rs have funded key clinical ICD studies and may fund
uture studies of implant capacity, unmet need, and barriers
o therapy. When evaluating such studies, assumptions,
ethods, and funding must be considered critically.
HE BIG PICTURE
he implantation of ICDs is only one step in the therapeu-
ic use of a technologically complex system that can cause
erious short-term and long-term complications. Implant-
ble cardioverter defibrillator therapy is a key element, but
nly one element, in a complex chain of comprehensive
ntiarrhythmic therapy.
Both the reliable sensing of VF and safe and effective
efibrillation are crucial for effective ICD therapy, but
either can be assured at implant without some risk to the
atient. Ideal implant testing would identify both the
ptimal ICD system for each patient and its optimal
rogramming, without the need for either VF or shocks.
ntil such a method is developed, implanters will benefit
rom new, practical, evidence-based guidelines on optimal
se of available methods. In the short term, guidelines may
ecommend less testing, more testing, or different (e.g.,
ulnerability) testing, depending on the clinical situation. In
he long term, they may recommend no testing if supported
y the level of evidence proposed by the authors. The goal
f reassessing implant testing should be to determine the
ptimal balance between implant safety and long-term
enefits of ICD therapy. To abandon implant testing is to
quander a valuable opportunity to improve outcomes for
CD patients.Available evidence indicates that nationwide ICD
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Editorial Comment July 7, 2004:92–4mplant capacity is not presently restricted by either the
equirement for implant testing or training requirements
or implanters. There are no waiting lists for ICDs.
lthough implant capacity should be sufficient for unmet
eed, excess implant capacity should not drive need. The
nalysis of barriers to therapy for prevention of arrhyth-
ic death should include all steps in the complex chain
equired for safe, effective, and comprehensive antiar-
hythmic therapy.
eprint requests and correspondence: Dr. Charles D. Swerd-
ow, Cedars-Sinai Medical Center, 8635 West Third Street, Suite
190 W, Los Angeles, California 90048. E-mail: swerdlow@
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